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We read with interest the article by Feuerstein et al. ‘Systematic analysis and critical 
appraisal quality of the scientific evidence and conflicts of interest in practice guidelines 
(2005 - 2013) for Barrett’s esophagus. We note the omission of our international consensus 
guidelines on management of Barrett’s esophagus [1,2] from this appraisal. While our 
guideline on the management of non-dysplastic and low grade dysplasia in Barrett’s 
oesophagus ‘BOB CAT’ [2] is outside the date limits of the search for evidence, our 2012 
guideline ‘BAD CAT’ [1] should have been retrieved by their search for evidence. This 
guideline was funded and endorsed by numerous international societies and the resulting 
publication is highly cited and accredited by NICE (UK) [3].  BAD CAT [1] involved an 
international panel of 92 authors and 11,000 articles were assessed on the management of 
Barrett’s dysplasia and early-stage esophageal adenocarcinoma.  Since the management of 
Barrett’s with dysplasia was not explicitly excluded from the review, it appears that there is 
no rationale for the exclusion of the BAD CAT guideline. Had our guideline been included, 
the authors would have noted that we addressed many of the problems and shortcomings 
identified by their review of other guidelines using the AGREE II instrument. Specifically, we 
assessed both the quality of the scientific evidence included in the review using GRADE [4] 
and reported conflict of interest declarations in detail. The guideline production method 
was inclusive, with input from all areas of clinical specialty and patient groups; there was 
consideration of adverse events and harms; it was peer-reviewed prior to publication and 
we identified areas which were directly applicable to clinical management. As an evidence-
based consensus group, we sought to maintain editorial independence and collected 
information about conflict of interest. Any participants who did not provide a conflict of 
interest statement were excluded from authorship, to ensure the impartiality of the 
process.   
Despite the omission of “most far-reaching, inclusive, and informative consensus process on 
evaluation and management of BE with HGD/early cancer published to date” [1], we can 
agree with Feuerstein et al. that the overall quality of evidence in most guidelines for 
Barrett’s esophagus is low [1], or in our later guideline [2], at best moderate. This paucity of 
higher quality evidence brings the reliability of clinical guidelines for the management of 
Barrett’s esophagus guidelines into question.  In both of our guidelines, we identified that 
there are urgent areas for research, including identifying genetic markers to determine 
cancer risk, determining the risk of progression from dysplasia into cancer and evaluating 
the most appropriate surveillance strategies for people diagnosed with Barrett’s esophagus. 
There are clinical trials in progress (e.g. AspECT [5], ChOPIN, EAGLE and BOSS [6]) which will 
help to inform future management of Barrett’s.  Our recently reported large-scale evidence-
based consensus guideline (also accredited by NICE (UK)[7]) on the management of non-
dysplastic Barrett’s and low grade dysplasia ‘BOB CAT’ [2], involved a panel of over 130 
people with special interest in Barrett’s, who reviewed over 20,000 publications.   
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